MedPlus Q1 FY27: Growth stayed strong, but margins faced multiple headwinds

MedPlus Health Services Limited reported a strong start to FY27 on the top line, but the quarter clearly showed pressure on profitability. Consolidated revenue for Q1 FY27 rose 21.8% year on year to 18,796 million. Operating EBITDA, however, declined to 651 million from 728 million in Q1 FY26, and the operating EBITDA margin fell to 3.5% from 4.7%.

The company also missed its Annual Operating Plan on profitability. Revenue achievement was close at 99.0% of AOP, but operating EBITDA came in at 81.6% of plan, reflecting the impact of a weaker gross margin and higher costs.

The quarter in one line: growth was healthy, mix and costs were not

The key operating issue in Q1 FY27 was a 160 basis point decline in consolidated gross margin to 24.5%. In the pharmacy segment, gross margin was 23.3%, down 170 basis points year on year. Management attributed the decline largely to a lower share of private label sales and lower margin realization in the franchisee business.

The cost side also moved up meaningfully. Consolidated shop-level expenses increased 14.0% year on year, while other expenses rose 34.3% year on year, driven by higher PSD expenses and corporate costs.

Financial snapshot (Q1 FY27)

Pharmacy: strong revenue, lower gross margin and employee cost pressure

Pharmacy remains the core business. Pharmacy revenue in Q1 FY27 rose 21.8% year on year to 18,398.7 million. But operating EBITDA declined to 588.1 million from 690.1 million last year, and the operating EBITDA margin fell to 3.2% from 4.6%.

In the investor deck, the company quantified the margin drivers. The decline in gross margin was attributed to two factors.

First, private label mix declined. The deck stated that 120 basis points of gross margin decline year on year was due to a lower private label sales mix. The category mix table showed private label pharma at 11.5% and private label non-pharma at 10.1% in Q1 FY27.

Second, the franchisee business carried a lower gross margin. The deck stated that about 50 basis points of the decline was due to lower margin realized in the franchisee business.

Costs also rose. Salaries at the shop level increased sharply year on year. During the earnings call, the CFO pointed to increases in wage levels, with a significant hike in Karnataka and Telangana, and explained that Q1 included only one month of the impact since the change was effective 1 June.

Management also outlined actions to mitigate pressure. In the call, the CFO said the company tweaked the discount structure effective 7 July, reducing the discount by 1% for purchases above 1,000 for a large number of customers. The company is also reviewing incentive structures, including private label incentives, in light of higher wage levels.

Network expansion: 5,476 pharmacies with franchise driving new additions

Store expansion continued at scale. As of 30 June 2026, MedPlus operated 5,476 pharmacies, comprising 4,812 company-owned company-operated stores and 664 franchisee stores.

Net addition in Q1 FY27 was 146 stores, with management highlighting that 131 net additions were franchisee stores. The company also provided a detailed breakdown of closures and conversions. It closed 52 stores during the quarter, including 27 franchisee withdrawals, and said 24 stores were in the process of conversion from COCO to franchise.

On the call, management reiterated guidance to add 800 net new stores in FY27, including franchisees. The franchise model was described as experimental, with management acknowledging that some franchisees exited due to expectation mismatch, but also emphasizing that the model is central to scaling the network to much larger levels over the long term.

Diagnostics: improving profitability, but management still wants more traction

Diagnostics remained a smaller contributor to consolidated revenue, but the trajectory on profitability improved. Diagnostics revenue in Q1 FY27 increased 22.4% year on year to 370.8 million.

Operating EBITDA in diagnostics rose to 65.9 million, and the operating EBITDA margin expanded to 17.8% from 13.6% in Q1 FY26. Operating EBIT also improved to 31.2 million.

During the call, the CEO said diagnostics is profitable but has not yet reached the scale and subscription traction the company wanted, particularly on the B2B side. Management noted that active clients were around 2 lakh as of end of June, and shared monthly run rates of plan sales.

Capital allocation: non-core capex paused after investor feedback

The sharpest governance and capital allocation discussion in the call was around non-core capex proposals. Management stated that board-approved capex proposals were put on hold. Participants referred to these as including a food park and oil extraction unit and a wellness or concierge initiative.

The CEO acknowledged that the market reaction was strong and investors expressed discomfort, and therefore the company chose to pause these plans. Management emphasized that core capex in the pharmacy and warehousing business continues.

The CFO also indicated that the company is evaluating options for deploying cash, including dividends or a share buyback, and would update the market in a future quarter if there is an outcome.

Key takeaways from Q1 FY27

MedPlus delivered strong revenue growth and continued expanding its store network, with franchise scaling playing an increasingly large role in new additions. The weak point of the quarter was profitability, driven by a softer private label mix, lower franchisee margins, and rising employee costs.

Management has outlined tactical actions such as discount structure changes and incentive optimization, and has indicated that private label mix recovery will take a couple of quarters. The decision to put non-core capex proposals on hold was the most significant change in stance during the quarter, showing responsiveness to investor feedback.

For investors, the near-term monitorables are straightforward. They are private label share recovery, the impact of wage hikes on operating costs, and whether the company can restore operating EBITDA margin closer to the levels implied in its annual operating plan, while still delivering its 800 net store addition guidance.